Our latest news & publications
OSE Immunotherapeutics - Apr 2021, 27th
COVID-19 Vaccine - CoVepiT : One of the first biodrugs combining biological technology and peptides designed with AI by MAbSilico authorizes to enter in clinical trial
The collaboration with MAbSilico has accelerated the discovery and the design of the best peptides in only 2 weeks compared to 6 to 12 months with conventional approaches. This discovery allows broad targeting ready for virus evolution, increasing the immune response and covering all initial and new strains and variants of SARS-CoV-2. Entering clinic of the first covid vaccine incorporating AI engineered peptides. OSE Immunotherapeutics receives approval to proceed with Phase 1 clinical trial of its COVID-19 vaccine.
MAbSilico - Apr 2021, 24th
MAbSilico is at the Biologics series conference 26th - 27th April
MAbSilico, bronze sponsor of the Biologics series and will present its technology during the conference. Join us to learn how AI-solutions are used to accelerate and secure the discovery of antibody drugs. A roundtable will take place the 26th with Dr. Morello, scientist at OSE Immunotherapeutics to provide feedbacks about how they use MAbSilico technology in their discovery workflow. They used MAbSilico's technology to design peptides used for the development of a Covid-19 vaccine which is in clinic trial taday.
MAbSilico - Mar 2021, 04th
Sanofi iTech Awards
MAbSilico is happy to be part of the 11 projects of the #iTechAwards selected by Sanofi. Our Artificial Intelligence solutions are selected to be used for Sanofi R&D in antibody development programs. In partnership with BPI france, the iTech Awards aims to identify and test new technologies for Sanofi R&D projects. MAbSilico will benefit from funding and scientific support throughout their projects
MAbSilico - Jan 2021, 06th
Exploring epitope and functional diversity of anti-SARS-CoV2 antibodies using AI-based methods.
Since the beginning of the COVID19 pandemics, an unprecedented research effort has been conducted to analyze the antibody responses in patients, and many trials based on passive immunotherapy — notably monoclonal antibodies — are ongoing. Twenty-one antibodies have entered clinical trials, 6 having reached phase 2/3, phase 3 or having received emergency authorization. The main problem facing laboratories willing to develop such antibodies is the huge task of analyzing them and choosing the best candidate for exhaustive experimental validation. In this work we show how artificial intelligence-based methods can help in analyzing large sets of antibodies in order to determine in a few hours the best candidates in few hours. We use MAbTope to predict the epitopes for all antibodies for which they are not already known. This allows an exhaustive comparison of the available epitopes, but also gives a synthetic view of the possible combinations. Finally, we show how these results can be used to predict which antibodies might be affected by the different mutations arising in the circulating strains of the virus, such as the N501Y mutation that has started to spread in Great-Britain.
Frontiers in Immunology - Sep 2020, 29th
4C3 Human Monoclonal Antibody: A Proof of Concept for Non-pathogenic Proteinase 3 Anti-neutrophil Cytoplasmic Antibodies in Granulomatosis With Polyangiitis
Granulomatosis with polyangiitis (GPA) is a severe autoimmune vasculitis associated with the presence of anti-neutrophil cytoplasmic antibodies (ANCA) mainly targeting proteinase 3 (PR3), a neutrophilic serine proteinase. We obtained for the first time a non-activating human IgG1κ anti-PR3 monoclonal antibody (mAb) named 4C3. This new mAb binds soluble PR3 with a high affinity and membrane-bound PR3 on an epitope close to the PR3 hydrophobic patch and in the vicinity of the active site.
Front. Immunol., Sept. 2020 DOI:10.3389/fimmu.2020.573040
anti-neutrophil cytoplasmic antibodies, proteinase 3, granulomatosis with polyangiitis, epitope, human neutrophils; AI; antibody characterization; drug discovery
Cancer Science - May 2020, 05th
Biasing HER4 Tyrosine Kinase Signaling with Antibodies: Induction of Cell Death by antibody-dependent 4ICD Trafficking
In this paper, we demonstrated that Neuregulin 1 (NRG1) induces cell death through JMa/CYT1 HER4 retention into mitochondria, and selected anti-HER4 antibody C6 mimics these NRG1-induced effects leading to tumor growth regression of ovarian and breast cancer xenografts
Cancer Sci, May 2020, PMID: 32415868, DOI: 10.1111/cas.14458
NRG1; HER4/ErbB4; tumor suppressor; therapeutic antibody; drug discover; AI
Methods in Molecular Biology - Mar 2019, 05th
Methods to Determine Interaction Interfaces Between β-Arrestins and Their Protein Partners
We present here a method in two steps: protein–protein docking allows finding a limited number of peptides predicted to be involved in the interaction, and then experimental approaches that might be used for validating the prediction.
Methods Mol Biol., Mar 2019, PMID: 30919355, DOI: 10.1007/978-1-4939-9158-7_12
proteincomplex; β-arrestin partners; Interface region; Protein–protein docking; AI
Journal for ImmunoTherapy of Cancer - Feb 2019, 05th
Immunotherapy of triple-negative breast cancer with cathepsin D-targeting antibodies
This study explores whether cath-D is a tumor cell-associated extracellular biomarker and a potent target for antibody-based therapy in TNBC.
J ImmunoTher Cancer, Feb 2019, PMID: 30717773, DOI: 10.1186/s40425-019-0498-z
TNBC; Human antibody based therapy; Immunomodulation; Protease; Tumor microenvironment; Phage display; AI; drug discovery
mAbs - Feb 2019, 05th
A recycling anti-transferrin receptor-1 monoclonal antibody as an efficient therapy for erythroleukemia through target up-regulation and antibody-dependent cytotoxic effector functions
Targeting TfR1 using the fully human anti-TfR1 H7 is a promising tool for the treatment of leukemia and lymphoma.
mAbs, Feb 2019, PMID: 30604643, DOI: 10.1080/19420862.2018.1564510
Transferrin receptor 1; iron metabolism; leukemia; therapeutic antibody; AI
The Journal of Immunology - Oct 2018, 09th
MAbSilico is happy to announce the release of the scientific paper "MAbTope" in the Journal of Immunoly.
Discover our tools MAbTope and how this AI-driven solution can accelerate and secure the intellectual property of you antibodies. Based on the Ab sequence, perform quick and reliable epitope mapping.
J Immunol , October 15, 2018, ji1701722; DOI: https://doi.org/10.4049/jimmunol.1701722
Drug Discovery; AI; antibody characterization
FASEB - Mar 2018, 06th
G protein–dependent signaling triggers a β-arrestin–scaffolded p70S6K/ rpS6 module that controls 5′TOP mRNA translation
This work highlights new relationships between G proteins and β-arrestins when acting cooperatively on a common signaling pathway, contrasting with their previously shown parallel action on the ERK MAP kinase pathway. In addition, this study provides insights into how GPCR can exert trophic effects in the cell.
FASEB J, Mar 2018, PMID: 29084767, DOI: 10.1096/fj.201700763R
GPCR; FSHR; gene regulation; AI; Drug Discovery
Journal of thrombosis and haemostasis - Aug 2017, 08th
5B9, a monoclonal antiplatelet factor 4/heparin IgG with a human Fc fragment that mimics heparin-induced thrombocytopenia antibodies
5B9 is the first anti‐PF4/H monoclonal antibody with a human Fc fragment, which induces similar cellular activation as HIT antibodies. Moreover, 5B9 binds epitopes within PF4 that are likely to be critical for the pathogenicity of HIT antibodies.
J Thromb Haemost, Aug 2017, PMID: 28771917, DOI: 10.1111/jth.13786
heparin; monoclonal antibody; platelet activation; thrombocytopenia; AI; Drug Discovery
mABs - Jun 2017, 06th
Antibodies targeting G protein-coupled receptors: Recent advances and therapeutic challenges
The conference ended with the consensus that Abs and especially nanobodies are opening a new era of research on GPCR structure, pharmacology and pathophysiology.
mAbs, Jun 2017, PMID: 28475474, DOI: 10.1080/19420862.2017.1325052
Antibody; biopharmaceuticals; GPCR; G protein; nanobody; phage display; β-arrestin; AI; Drug Discovery
Molecular Immunology - Sep 2016, 06th
Eculizumab epitope on complement C5: Progress towards a better understanding of the mechanism of action
Sequence analysis, in silico docking and reverse phase protein array were implemented to fully characterize the eculizumab epitope on human complement C5.
Mol Immunol, Sep 2016, PMID: 27497837, DOI: 10.1016/j.molimm.2016.07.016
Eculizumab; Complement C5; Molecular docking; Conformational epitope; Mechanism of action; Therapeutic antibody; AI
MAbSilico - Jan 2021, 20th
MAbSilico Expands its Collaboration with OSE Immunotherapeutics
In less than a year MAbSilico demonstrated that our AI-based software is a key advantage for OSE Immunotherapeutics to accelerate their antibody drugd iscovery programs. This new agreement signed with OSE focus on the use of Artificial Intelligence to accelerate drug development of novel antibody therapeutics. OSE is advancing an "Immunotherapy 2.0" future by leveraging MAbSilico’s artificial intelligence-powered software solutions and professional services to accelerate and further optimize the development of new therapeutic monoclonal antibodies. MAbSilico and OSE joined their efforts to demonstrate the power of a fully computational in silico Antibody Discovery and Design platform. The expanded collaboration agreement will now be applied to 10 antibody programs.
MAbSilico - Jun 2020, 23rd
MAbSilico deploys its AI tools for a fast response in context of pandemic threat
The use of MAbSilico technologies accelerates the development of antibodies drug candidates against SARS-CoV-2
In the context of the Covid-19 crisis, MAbSilico deploys its AI technologies to develop faster antibody drug candidates against SARS-CoV-2. Within a group of experts gathered around MAbSilico, the use of two tools is engaged to deliver candidates in a few weeks:
i/The antibody maturation with MAbMature® method is used to convert anti-SARS-CoV antibodies into anti-SARS-CoV2 antibodies (cf figure, strategy 1). Previously described anti-SARS-Co-V antibodies have already been identified, like the one shown in the figure which inhibits the binding of the spike protein on its receptor ACE2 and subsequent viral entry in its target cells. The comparison between the scFv epitopes on the spike proteins of SARS-CoV and SARS-CoV-2 (this latter one being defined by MAbSilico’s method MAbTope®) shown that the homology between the 2 proteins in the VL interface is too low to predict an actual binding of the scFv on SARS-CoV-2 spike. MAbMature® method is thus applied only to the VH domain which matured CDRs are illustrated in red.
ii/ The antibody selection method MAbSelect® (cf figure, strategy 2) which combines MAbSilico’s similarity-based antibody clustering and affinity prediction methods in the aim of retrieving anti-SARS-Cov2 antibodies from healed patients’ blood samples.
The antibodies drug candidates identified by both methods will be tested in vitro and in vivo.
By engaging these developments, MAbSilico creates a fast track and breakthrough pipeline for antibody drug candidates development to react to the next pandemics.
BioKorea - May 2020, 05th
MAbSilico presents its tools at the BIO Korea in partnership with Y-Biologics.
MAbSilico is presenting its AI-driven solutions during the BIO Korea in May 2020 with its collaborator in South Korea Y-Biologics. BIO Korea is the Asia's Biggest Bio Convention, a substantive place of business with international information exchange, and technology transfer and has invigorated the bio industry for many years celebrating its 15th anniversary of leading Korean bio-industry’s future. Anne Poupon is presenting "Artificial Intelligence Methods for Therapeutic Antibodies Characterization" during the therapeutic antibody session.
Join Us for this virtual presentation #antibody #drugdiscovery #drugdevelopment #insilico #AI
OSE - Feb 2020, 04th
MAbSilico and OSE Immunotherapeutics announce their collaboration.
MAbSilico and OSE immnotherapeutics sign a collaboration for the use of artificial intelligence in antibody development. OSE Immunotherapeutics plans to incorporate innovative problem-solving solutions like AI for the development of new monoclonal antibodies. MAbSilico solutions have already been tested and validated by OSE Immunotherapeutics and will be used for six antibody programs, including novel bispecific antibodies. AI and numerical simulation can guide therapeutic antibody discovery, help reduce the risk of failure and accelerate the pre-clinical development process of these drug candidates before clinical tests.
Bpifrance - Dec 2019, 17th
MAbSilico awarded for a 1 M€ grant in the Bpifrance i-Nov competition.
MAbSilico has just been attributed a grant of one million euros in the Bpifrance I-Nov competition. This rewards its software, which uses artificial intelligence and numeric simulation to guide therapeutic antibody discovery, reducing the risk of failure and the time during the development of these drug candidates before clinical tests. A revolution in the bio-drugs development process.
MabImprove - Jun 2019, 04th
MAbSilico presents its new tools at the 7th Antibody Industrial Symposium.
The 7th Antibody Industrial Symposium (AIS2019) will be held the 24th and 25th of June 2019 in Tours, France. This congress, jointly organized by the scientific society LabEx MAbImprove and the industrial organization MabDesign, is part of the series of Industrial Symposia organized by MAbImprove since 2013 (Antibodies Biosimilars, MAbDosing, MAbDelivery, Current & Next Generation Antibody Formats, Antibody Drug Conjugates).
Join Us at the #7AIS2019 Congress @congress_ais – 24/25 June – Tours FR. #innovativeapproaches #therapeuticAbs #mAbs #immunotherapy
MAbSilico - Apr 2019, 08th
MAbSilico presents its tools at the 12th Annual Proteins & Antibodies Congress.
At the annual Proteins & Antibodies Congress, MAbSilico will present the in silico tools with our partner Synthelis for antibody development among the best speakers from big pharma, biotechs, academia and technology innovators. Come to discuss about the most exciting breakthroughs for the discovery and development of antibodies.
Come to visit us during our presentation session.
MAbSilico - Apr 2019, 02nd
MAbSilico is supporting the conference "Intelligence Artificielle & Développement des immunothérapies ".
This event in Lyon gather the French companies and organization using Artificial Intelligence for the development of immunotherapies..
Come to visit us at our booth.
MAbSilico - Oct 2018, 02nd
MAbSilico presents its technology at the European Antibody Congress.
At the European Antibody Congress, MAbSilico will present the in silico methods for antibody development among the best speakers from big pharma, biotechs, academia and technology innovators to discuss the most exciting breakthroughs when it comes to the discovery and development of antibodies.
Come to visit us at the booth or during the poster session.
MAbSilico - Jun 2018, 05th
MAbSilico and Synthelis sign a commercial agreement to promote a joint service offering.
As of June 21, 2018, Synthelis and MAbSilico combine their know-how and thus capitalize on their respective technology in developing a joint offer through a commercial agreement, responding to the needs of their customers.
This offer combines the cutting-edge expertise of two recognized players in their respective domain: MAbSilico with its in silico method to characterize antibodies at their early stage of development and Synthelis, for its cell-free patented technology.
MAbSilico - Jun 2018, 01st
MAbSilico is talking at the 6th Antibody Industrial Symposium.
The 6th Antibody Industrial Symposium 2018 (AIS2018) will be held the 25th and 26th of June 2018 in Montpellier, France. This congress, jointly organized by the scientific society LabEx MAbImprove and the industrial organization MabDesign, is part of the series of Industrial Symposia organized by MAbImprove since 2013 (Antibodies Biosimilars, MAbDosing, MAbDelivery, Current & Next Generation Antibody Formats, Antibody Drug Conjugates).
MAbSilico - Mar 2018, 06th
MAbSilico is selected to be accelerated at Le Château.
Le Château is an accelerating program for early stage startups.
MAbSilico - Dec 2017, 05th
MAbSilico is talking at the Immunotherapies for Infectious Diseases Congress
The second edition of the Immunotherapies for Infectious Diseases Congress - I4ID, that will be held in Lyon (France) on December 10-11, 2018, this year dedicated to Host-Directed Therapies (HDT) to fight infectious diseases.
MAbSilico - Oct 2017, 10th
MAbSilico is selected in the top 500 startups at the Hello Tomorrow Global Challenge
The Hello Tomorrow Challenge is the world’s biggest early-stage startup competition for science and deep technology startups. Each year, they identify the best projects of the Challenge to attend the Hello Tomorrow Summit in Paris, an invite-only event bringing together the people that will change the world using science and technology around top investors in each sector, industrial leaders (Airbus, Google[x], Carrefour, Merck, Air Liquide, Facebook, etc.), international media (Bloomberg, BBC, Wired, etc.) and influencers (in 2016, Mike Bloomberg, Emmanuel Macron, CTO of Meta, CEO of Unity Biotech, etc).
MAbSilico - Oct 2017, 03rd
MAbSilico is at the Next-Generation Antibodies and Protein Analysis
Catalyzed by VIB’s Technology Scouting team, the Tools and Technologies meetings focus on the front end of innovation and bring together key innovators in selected life sciences research fields. The Next-Generation Antibodies and Protein Analysis conference, in Ghent (Belgium), is set to make another world class meeting, bringing together an exciting selection of top speakers and newly emerged companies. In addition to great scientific and technology program, the conference will provide ample networking opportunities.
Bpifrance - Oct 2017, 03rd
MAbSilico received the "Bourse French Tech" from Bpifrance
Good start for MAbSilico
MAbSilico - Sep 2017, 26th
MAbSilico is founded
We are happy to announce the incorporation of MAbSilico.
1 impasse du Palais 37000 Tours